GT Biopharma, Inc.
No enriched coverage for $GTBP in the last 7 days.
No SEC Form 4 filings for $GTBP in the last 30 days.
GT Biopharma Provides Enrollment Update on GTB-3650 Phase 1 Trial in Patients with Relapsed or Refractory (r/r) CD33 Expressing Hematologic Malignancies ...
Clinical-stage immuno-oncology company GT Biopharma Inc. ( NASDAQ:GTBP ) announced on Wednesday that enrollment in the dose escalation cohorts of the Phase 1 trial of GTB-3650 for relapsed or refractory CD33-expressing hematologic malignancies is on track.
SAN FRANCISCO, CALIFORNIA, Oct. 06, 2025 ( GLOBE NEWSWIRE ) -- GT Biopharma, Inc. ( the "Company" ) ( NASDAQ: GTBP ) , a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Company's proprietary natural killer ( NK ) cell engager TriKE® platform, ...
